Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How Has The Cardiac Amyloidosis Market Growth Evolved From 2024 To 2025, And What’s Ahead?
Strong growth has been observed in the cardiac amyloidosis market size in recent years. It is estimated to expand from $5.26 billion in 2024 to $5.75 billion in 2025, with a compound annual growth rate (CAGR) of 9.2%. Factors influencing this historic growth include an increase in the prevalence of conditions related to amyloidosis, a rise in genetic mutations, improved awareness, an increase in cases of transthyretin amyloidosis, and a growing elderly population.
The market for cardiac amyloidosis is projected to experience robust expansion in the coming years. By 2029, it is anticipated to reach a worth of $8.10 billion, with a compound annual growth rate (CAGR) of 9.0%. This market growth during the forecast period can be credited to factors such as enhanced diagnostic rates, governmental assistance and strategic actions, an increase in genetic mutation prevalence, and programs designed specifically for patients. The upcoming trend for this market will feature the development of innovative therapies including vulrisiran, increased investigation in gene therapy, a push towards precision medicine, progression in diagnostic tools, and the creation of unique treatments.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21128&type=smp
Which Factors and External Forces Are Driving Demand in the Cardiac Amyloidosis Market?
The cardiac amyloidosis market’s growth is anticipated to be driven by the rising elderly population. This refers to those aged 65 and over, who often require certain types of healthcare and support due to the effects of aging. The increase in this population segment can be attributed to longer life expectancy, healthcare improvements, and a decrease in birth rates. Consequently, the chances of cardiac amyloidosis occurrence rise as aging presents a significant risk factor for the accumulation of amyloid protein in the heart. For example, the Population Reference Bureau, a nonprofit organization based in the US, projected in January 2024 that the number of US residents aged 65 and older will boost from 58 million in 2022 to 82 million in 2050, reflecting a 47% surge. This growth in the elderly population will, therefore, likely stimulate the cardiac amyloidosis market.
Which Segments in the Cardiac Amyloidosis Offer the Most Growth?
The cardiac amyloidosis market covered in this report is segmented –
1) By Product Type: Light Chain Amyloidosis, Transthyretin Amyloidosis
2) By Treatment: Chemotherapy, Surgery, Supportive Care, Stem Cell Transplant, Targeted Therapy
3) By End-User: Hospitals, Ambulatory Surgical Centres, Clinics
Subsegments:
1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis, Primary Light Chain Amyloidosis, Secondary Light Chain Amyloidosis
2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm), Wild-type Transthyretin Amyloidosis (ATTRwt)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21128&type=smp
What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Cardiac Amyloidosis Market?# Market?
North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Cutting-Edge Market Trends Are Expected to Drive theCardiac Amyloidosis Market’s Growth?
Leading firms in the cardiac amyloidosis sector are concentrating on cutting-edge technological advancements, such as diagnostic tools that rely solely on artificial intelligence (AI). These aim to bolster early identification and amplify clinical outcomes for people suffering from this frequently undetected ailment. A medical device that detects cardiac amyloidosis, solely based on AI software, is a diagnostic tool employing AI for echocardiographic image analysis and disease sign identification, eliminating the need for additional hardware or comprehensive clinical data. As an example, in November 2024, the UK-based health tech firm Ultromics Ltd. gained FDA approval for EchoGo Amyloidosis, an AI-utilizing clinical tool, designed for the early detection of cardiac amyloidosis. This device marks the first to achieve marketing authorization in the FDA’s Total Product Lifecycle Advisory Program (TAP). EchoGo Amyloidosis, leveraging AI, probes echocardiograms to diagnose the ailment from a single clip, hence addressing the pressing need for earlier detection before progression unnoticed.
View the full report here:
https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report
What Are the Key Elements That Define the Cardiac Amyloidosis Market?
Cardiac amyloidosis is a condition where abnormal amyloid protein deposits in the heart tissue, leading to stiffening and impaired function. This results in heart failure, arrhythmias, and other cardiovascular complications. Early diagnosis and treatment are crucial to managing symptoms and slowing disease progression.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21128
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
